Brought to you by 
Biofrontera and Kiadis ally on neuropathic pain therapeutics
19 Apr 2021
Executive Summary
Kiadis BV (identifies biologically active compounds) will apply its high resolution technology to disease targets provided by Biofrontera Pharmaceuticals GMBH (drug discovery for nervous system disorders, Alzheimer's and Parkinson's diseases, and schizophrenia) to discover and develop drug candidates for neuropathic pain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biofrontera and Kiadis ally on neuropathic pain therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice